PUBLISHER: Market Research Future | PRODUCT CODE: 1396614

PUBLISHER: Market Research Future | PRODUCT CODE: 1396614

Nanobody Market Research Report Forecast till 2030

PUBLISHED: December 13, 2023

PAGES: 128 Pages

DELIVERY TIME: 1-2 business days

SELECT AN OPTION

Nanobody Market is anticipated to register a significant market expansion at a CAGR of 17.88% during the forecast period. The rising pervasiveness of constant sicknesses, rising interest for accuracy medication, and expanding interest in nanobody innovative work are driving market development.

Nanobodies are little immunizer sections that enjoy a few upper hands over conventional antibodies, like more prominent dependability, better tissue entrance, and decreased immunogenicity. The rising commonness of immune system infections and other ongoing issues requests the revelation of fresher and more compelling nanobody-based drugs for their treatment. For example, in February 2019, the US Food and Medication Organization (FDA) endorsed Cablivi (caplacizumab-yhdp), the main nanobody-based medication of Sanofi S.A. (France), for grown-ups with gained thrombotic thrombocytopenic purpura (aTTP).

As indicated by the World Wellbeing Association (WHO), constant infections like malignant growth, cardiovascular sickness, and diabetes are answerable for 74% of all passings universally. The occurrence and predominance of these illnesses are supposed to keep on rising, driven by elements like maturing populaces, evolving ways of life, and expanding urbanization. Subsequently, the rising commonness of persistent infections, joined with the extraordinary benefits of nanobodies drives the market development.

Market Segmentation

Based on type the Nanobody Market is bifurcated into mono-specific and multi-specific. Based on application the market is divided into therapeutic, diagnostic, and research. The therapeutic segment is further segmented into cancer, neurodegenerative diseases, infectious diseases, and others. The Nanobody Market based on end user is classified into pharmaceutical & biotechnology companies, research laboratories, and others.

Regional Insights

The North America nanobody market represented the biggest market share in 2022. This is because of the great mindfulness related with nanobodies innovation in drug revelation and advancement to diminish the expense of creation in the North American area.

Europe nanobody market represents the second-biggest market share because of the presence of dynamic market players, developing nanobodies new businesses, and expanding predominance of illnesses, for example, irresistible, neurological, and disease. further, Germany nanobody market was ascribed to hold the biggest market share, and the France nanobody market is supposed to quickest developing market in the European locale.

The Asia-Pacific nanobody market is supposed to develop at a huge share from 2023 to 2030. This is because of the developing geriatric populace, expanding predominance of malignant growth and irresistible sicknesses, and further developing examination abilities in the Asia-Pacific locale.

The Remainder of the World is sectioned into the Center East, Africa, and Latin America. The nanobody market in the previously mentioned locales is probably going to observe development because of the rising pervasiveness of irresistible illnesses and the rising predominance of non-transferable sicknesses.

Major Players

Key Companies in the Nanobody Market include Sanofi (France), Merck KGaA (Germany), BIOCYTOGEN (US), Proteintech Group, Inc (US), Novartis AG (Switzerland), GenScript (US), Sensei Biotherapeutics, Inc (US), Beroni Group (Australia), ExeVir Bio (Belgium), Taisho Pharmaceutical Holdings Co., Ltd (Japan), and DiosCURE Therapeutics SE (Germany).

Product Code: MRFR/HC/9539-CR

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 LIST OF ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY

3.1 DATA MINING
3.2 SECONDARY RESEARCH
3.3 PRIMARY RESEARCH
- 3.3.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
- 3.3.2 BREAKDOWN OF PRIMARY RESPONDENTS
3.4 FORECASTING TECHNIQUES
3.5 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
- 3.5.1 BOTTOM-UP APPROACH
- 3.5.2 TOP-DOWN APPROACH
3.6 DATA TRIANGULATION
3.7 VALIDATION

4 MARKET DYNAMICS

4.1 OVERVIEW
4.2 DRIVERS
- 4.2.1 INCREASING PREVALENCE OF CHRONIC DISEASES
- 4.2.2 RISING DEMAND FOR PRECISION MEDICINE
- 4.2.3 INCREASING INVESTMENT IN NANOBODY RESEARCH AND DEVELOPMENT
4.3 RESTRAINTS
- 4.3.1 MANUFACTURING CHALLENGES AND HIGH PRODUCTION COSTS
4.4 OPPORTUNITY
- 4.4.1 GROWING DEVELOPMENT OF NEW APPLICATIONS OF NANOBODIES

5 MARKET FACTOR ANALYSIS

5.1 VALUE CHAIN ANALYSIS
- 5.1.1 R&D
- 5.1.2 MANUFACTURING
- 5.1.3 DISTRIBUTION AND SALES
- 5.1.4 POST-SALES MONITORING
5.2 PORTER'S FIVE FORCES MODEL
- 5.2.1 THREAT OF NEW ENTRANTS
- 5.2.2 BARGAINING POWER OF SUPPLIERS
- 5.2.3 THREAT OF SUBSTITUTES
- 5.2.4 BARGAINING POWER OF BUYERS
- 5.2.5 INTENSITY OF RIVALRY
5.3 IMPACT OF COVID-19 ON THE GLOBAL NANOBODY MARKET
- 5.3.1 IMPACT ON SUPPLY CHAIN
- 5.3.2 IMPACT ON CLINICAL TRIALS
- 5.3.3 IMPACT ON DEMAND AND SUPPLY

6 GLOBAL NANOBODY MARKET, BY TYPE

6.1 OVERVIEW
6.2 MONO-SPECIFIC
6.3 MULTI-SPECIFIC

7 GLOBAL NANOBODY MARKET, BY APPLICATION

7.1 OVERVIEW
7.2 THERAPEUTIC
- 7.2.1 CANCER
- 7.2.2 NEURODEGENERATIVE DISEASES
- 7.2.3 INFECTIOUS DISEASES
- 7.2.4 OTHERS
7.3 DIAGNOSTIC
- 7.3.1 DETECTION OF PROTEINS AND MICROORGANISMS
- 7.3.2 DETECTION OF SMALL MOLECULES
- 7.3.3 IMAGING
7.4 RESEARCH

8 GLOBAL NANOBODY MARKET, BY END USER

8.1 OVERVIEW
8.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
8.3 RESEARCH LABORATORIES
8.4 OTHERS

9 GLOBAL NANOBODY MARKET, BY REGION

9.1 OVERVIEW
9.2 NORTH AMERICA
- 9.2.1 US
- 9.2.2 CANADA
9.3 EUROPE
- 9.3.1 GERMANY
- 9.3.2 UK
- 9.3.3 FRANCE
- 9.3.4 ITALY
- 9.3.5 SPAIN
- 9.3.6 REST OF EUROPE
9.4 ASIA PACIFIC
- 9.4.1 JAPAN
- 9.4.2 CHINA
- 9.4.3 INDIA
- 9.4.4 SOUTH KOREA
- 9.4.5 AUSTRALIA
- 9.4.6 REST OF ASIA PACIFIC
9.5 REST OF THE WORLD
- 9.5.1 MIDDLE EAST
- 9.5.2 AFRICA
- 9.5.3 LATIN AMERICA

10 COMPETITIVE LANDSCAPE

10.1 OVERVIEW
10.2 COMPETITIVE BENCHMARKING
10.3 MAJOR GROWTH STRATEGY IN THE GLOBAL NANOBODY MARKET
10.4 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE GLOBAL NANOBODY MARKET
10.5 KEY DEVELOPMENT ANALYSIS
10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
- 10.6.1 PRODUCT LAUNCH/PRODUCT APPROVAL
- 10.6.2 MERGER/ ACQUISITION
- 10.6.3 PARTNERSHIP/ AGREEMENT/COLLABORATION
10.7 MAJOR PLAYERS SALES ANALYSIS
10.8 MAJOR PLAYERS R&D ANALYSIS

11 COMPANY PROFILES

11.1 SANOFI
- 11.1.1 COMPANY OVERVIEW
- 11.1.2 FINANCIAL OVERVIEW
- 11.1.3 PRODUCTS OFFERED
- 11.1.4 KEY DEVELOPMENTS
- 11.1.5 SWOT ANALYSIS
- 11.1.6 KEY STRATEGIES
11.2 MERCK KGAA
- 11.2.1 COMPANY OVERVIEW
- 11.2.2 FINANCIAL OVERVIEW
- 11.2.3 PRODUCTS OFFERED
- 11.2.4 KEY DEVELOPMENTS
- 11.2.5 SWOT ANALYSIS
- 11.2.6 KEY STRATEGIES
11.3 BIOCYTOGEN
- 11.3.1 COMPANY OVERVIEWS
- 11.3.2 FINANCIAL OVERVIEW
- 11.3.3 PRODUCTS OFFERED
- 11.3.4 KEY DEVELOPMENTS
- 11.3.5 KEY STRATEGIES
11.4 PROTEINTECH GROUP, INC.
- 11.4.1 COMPANY OVERVIEW
- 11.4.2 FINANCIAL OVERVIEW
- 11.4.3 PRODUCTS OFFERED
- 11.4.4 KEY DEVELOPMENTS
- 11.4.5 KEY STRATEGIES
11.5 NOVARTIS AG
- 11.5.1 COMPANY OVERVIEW
- 11.5.2 FINANCIAL OVERVIEW
- 11.5.3 PRODUCTS OFFERED
- 11.5.4 KEY DEVELOPMENTSS
- 11.5.5 SWOT ANALYSIS
- 11.5.6 KEY STRATEGIES
11.6 GENSCRIPT
- 11.6.1 COMPANY OVERVIEWS
- 11.6.2 FINANCIAL OVERVIEW
- 11.6.3 PRODUCTS OFFERED
- 11.6.4 KEY DEVELOPMENTS
- 11.6.5 SWOT ANALYSIS
- 11.6.6 KEY STRATEGIES
11.7 SENSEI BIOTHERAPEUTICS, INC
- 11.7.1 COMPANY OVERVIEW
- 11.7.2 FINANCIAL OVERVIEW
- 11.7.3 PRODUCTS OFFERED
- 11.7.4 KEY DEVELOPMENTS
- 11.7.5 SWOT ANALYSIS
- 11.7.6 KEY STRATEGIES
11.8 BERONI GROUP
- 11.8.1 COMPANY OVERVIEW
- 11.8.2 FINANCIAL OVERVIEW
- 11.8.3 PRODUCTS OFFERED
- 11.8.4 KEY DEVELOPMENTS
- 11.8.5 KEY STRATEGIES
11.9 EXEVIR BIO
- 11.9.1 COMPANY OVERVIEW
- 11.9.2 FINANCIAL OVERVIEW
- 11.9.3 PRODUCTS OFFERED
- 11.9.4 KEY DEVELOPMENTS
- 11.9.5 KEY STRATEGIES
11.10 TAISHO PHARMACEUTICAL HOLDINGS CO., LTD
- 11.10.1 COMPANY OVERVIEW
- 11.10.2 FINANCIAL OVERVIEW
- 11.10.3 PRODUCTS OFFERED
- 11.10.4 KEY DEVELOPMENTS
- 11.10.5 KEY STRATEGIES
11.11 DIOSCURE THERAPEUTICS SE
- 11.11.1 COMPANY OVERVIEW
- 11.11.2 FINANCIAL OVERVIEW
- 11.11.3 PRODUCTS OFFERED
- 11.11.4 KEY DEVELOPMENTS
- 11.11.5 KEY STRATEGIES

12 APPENDIX

12.1 REFERENCES
12.2 RELATED REPORTS

Product Code: MRFR/HC/9539-CR

LIST OF TABLES

TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS
TABLE 2 GLOBAL NANOBDOY MARKET, BY TYPE, 2019-2030 (USD BILLION)
TABLE 3 GLOBAL NANOBDOY MARKET, FOR MONO-SPECIFIC, BY REGION, 2019-2030 (USD BILLION)
TABLE 4 GLOBAL NANOBDOY MARKET, FOR MULTI-SPECIFIC, BY REGION, 2019-2030 (USD BILLION)
TABLE 5 GLOBAL NANOBDOY MARKET, BY APPLICATION, 2019-2030 (USD BILLION)
TABLE 6 GLOBAL NANOBDOY MARKET, FOR THERAPEUTIC, BY REGION, 2019-2030 (USD BILLION)
TABLE 7 GLOBAL NANOBDOY MARKET, FOR THERAPEUTIC, BY TYPE, 2019-2030 (USD BILLION)
TABLE 8 GLOBAL NANOBDOY MARKET, FOR CANCER, BY REGION, 2019-2030 (USD BILLION)
TABLE 9 GLOBAL NANOBDOY MARKET, FOR NEURODEGENERATIVE DISEASES, BY REGION, 2019-2030 (USD BILLION)
TABLE 10 GLOBAL NANOBDOY MARKET, FOR INFECTIOUS DISEASES, BY REGION, 2019-2030 (USD BILLION)
TABLE 11 GLOBAL NANOBDOY MARKET, FOR OTHERS, BY REGION, 2019-2030 (USD BILLION)
TABLE 12 GLOBAL NANOBDOY MARKET, FOR DIAGNOSTIC, BY REGION, 2019-2030 (USD BILLION)
TABLE 13 GLOBAL NANOBDOY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019-2030 (USD BILLION)
TABLE 14 GLOBAL NANOBDOY MARKET, FOR DETECTION OF PROTEINS AND MICROORGANISMS, BY REGION, 2019-2030 (USD BILLION)
TABLE 15 GLOBAL NANOBDOY MARKET, FOR DETECTION OF SMALL MOLECULES, BY REGION, 2019-2030 (USD BILLION)
TABLE 16 GLOBAL NANOBDOY MARKET, FOR IMAGING, BY REGION, 2019-2030 (USD BILLION)
TABLE 17 GLOBAL NANOBDOY MARKET, FOR RESEARCH, BY REGION, 2019-2030 (USD BILLION)
TABLE 18 GLOBAL NANOBDOY MARKET, BY END USER, 2019-2030 (USD BILLION)
TABLE 19 GLOBAL NANOBDOY MARKET, FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2019-2030 (USD BILLION)
TABLE 20 GLOBAL NANOBDOY MARKET, FOR RESEARCH LABORATORIES, BY REGION, 2019-2030 (USD BILLION)
TABLE 21 GLOBAL NANOBDOY MARKET, FOR OTHERS, BY REGION, 2019-2030 (USD BILLION)
TABLE 22 GLOBAL: NANOBODY MARKET, BY REGION, 2019-2030 (USD BILLION)
TABLE 23 NORTH AMERICA: NANOBODY MARKET, BY COUNTRY, 2019-2030 (USD BILLION)
TABLE 24 NORTH AMERICA: NANOBODY MARKET, BY TYPE, 2019-2030 (USD BILLION)
TABLE 25 NORTH AMERICA: NANOBODY MARKET, BY APPLICATION, 2019-2030 (USD BILLION)
TABLE 26 NORTH AMERICA: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019-2030 (USD BILLION)
TABLE 27 NORTH AMERICA: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019-2030 (USD BILLION)
TABLE 28 NORTH AMERICA: NANOBODY MARKET, BY END USER, 2019-2030 (USD BILLION)
TABLE 29 US: NANOBODY MARKET, BY TYPE, 2019-2030 (USD BILLION)
TABLE 30 US: NANOBODY MARKET, BY APPLICATION, 2019-2030 (USD BILLION)
TABLE 31 US: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019-2030 (USD BILLION)
TABLE 32 US: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019-2030 (USD BILLION)
TABLE 33 US: NANOBODY MARKET, BY END USER, 2019-2030 (USD BILLION)
TABLE 34 CANADA: NANOBODY MARKET, BY TYPE, 2019-2030 (USD BILLION)
TABLE 35 CANADA: NANOBODY MARKET, BY APPLICATION, 2019-2030 (USD BILLION)
TABLE 36 CANADA: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019-2030 (USD BILLION)
TABLE 37 CANADA: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019-2030 (USD BILLION)
TABLE 38 CANADA: NANOBODY MARKET, BY END USER, 2019-2030 (USD BILLION)
TABLE 39 EUROPE: NANOBODY MARKET, BY COUNTRY, 2019-2030 (USD BILLION)
TABLE 40 EUROPE: NANOBODY MARKET, BY TYPE, 2019-2030 (USD BILLION)
TABLE 41 EUROPE: NANOBODY MARKET, BY APPLICATION, 2019-2030 (USD BILLION)
TABLE 42 EUROPE: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019-2030 (USD BILLION)
TABLE 43 EUROPE: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019-2030 (USD BILLION)
TABLE 44 EUROPE: NANOBODY MARKET, BY END USER, 2019-2030 (USD BILLION)
TABLE 45 GERMANY: NANOBODY MARKET, BY TYPE, 2019-2030 (USD BILLION)
TABLE 46 GERMANY: NANOBODY MARKET, BY APPLICATION, 2019-2030 (USD BILLION)
TABLE 47 GERMANY: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019-2030 (USD BILLION)
TABLE 48 GERMANY: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019-2030 (USD BILLION)
TABLE 49 GERMANY: NANOBODY MARKET, BY END USER, 2019-2030 (USD BILLION)
TABLE 50 UK: NANOBODY MARKET, BY TYPE, 2019-2030 (USD BILLION)
TABLE 51 UK: NANOBODY MARKET, BY APPLICATION, 2019-2030 (USD BILLION)
TABLE 52 UK: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019-2030 (USD BILLION)
TABLE 53 UK: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019-2030 (USD BILLION)
TABLE 54 UK: NANOBODY MARKET, BY END USER, 2019-2030 (USD BILLION)
TABLE 55 FRANCE: NANOBODY MARKET, BY TYPE, 2019-2030 (USD BILLION)
TABLE 56 FRANCE: NANOBODY MARKET, BY APPLICATION, 2019-2030 (USD BILLION)
TABLE 57 FRANCE: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019-2030 (USD BILLION)
TABLE 58 FRANCE: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019-2030 (USD BILLION)
TABLE 59 FRANCE: NANOBODY MARKET, BY END USER, 2019-2030 (USD BILLION)
TABLE 60 ITALY: NANOBODY MARKET, BY TYPE, 2019-2030 (USD BILLION)
TABLE 61 ITALY: NANOBODY MARKET, BY APPLICATION, 2019-2030 (USD BILLION)
TABLE 62 ITALY: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019-2030 (USD BILLION)
TABLE 63 ITALY: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019-2030 (USD BILLION)
TABLE 64 ITALY: NANOBODY MARKET, BY END USER, 2019-2030 (USD BILLION)
TABLE 65 SPAIN: NANOBODY MARKET, BY TYPE, 2019-2030 (USD BILLION)
TABLE 66 SPAIN: NANOBODY MARKET, BY APPLICATION, 2019-2030 (USD BILLION)
TABLE 67 SPAIN: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019-2030 (USD BILLION)
TABLE 68 SPAIN: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019-2030 (USD BILLION)
TABLE 69 SPAIN: NANOBODY MARKET, BY END USER, 2019-2030 (USD BILLION)
TABLE 70 REST OF EUROPE: NANOBODY MARKET, BY TYPE, 2019-2030 (USD BILLION)
TABLE 71 REST OF EUROPE: NANOBODY MARKET, BY APPLICATION, 2019-2030 (USD BILLION)
TABLE 72 REST OF EUROPE: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019-2030 (USD BILLION)
TABLE 73 REST OF EUROPE: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019-2030 (USD BILLION)
TABLE 74 REST OF EUROPE: NANOBODY MARKET, BY END USER, 2019-2030 (USD BILLION)
TABLE 75 ASIA PACIFIC: NANOBODY MARKET, BY COUNTRY, 2019-2030 (USD BILLION)
TABLE 76 ASIA-PACIFIC: NANOBODY MARKET, BY TYPE, 2019-2030 (USD BILLION)
TABLE 77 ASIA-PACIFIC: NANOBODY MARKET, BY APPLICATION, 2019-2030 (USD BILLION)
TABLE 78 ASIA-PACIFIC: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019-2030 (USD BILLION)
TABLE 79 ASIA-PACIFIC: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019-2030 (USD BILLION)
TABLE 80 ASIA-PACIFIC: NANOBODY MARKET, BY END USER, 2019-2030 (USD BILLION)
TABLE 81 JAPAN: NANOBODY MARKET, BY TYPE, 2019-2030 (USD BILLION)
TABLE 82 JAPAN: NANOBODY MARKET, BY APPLICATION, 2019-2030 (USD BILLION)
TABLE 83 JAPAN: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019-2030 (USD BILLION)
TABLE 84 JAPAN: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019-2030 (USD BILLION)
TABLE 85 JAPAN: NANOBODY MARKET, BY END USER, 2019-2030 (USD BILLION)
TABLE 86 CHINA: NANOBODY MARKET, BY TYPE, 2019-2030 (USD BILLION)
TABLE 87 CHINA: NANOBODY MARKET, BY APPLICATION, 2019-2030 (USD BILLION)
TABLE 88 CHINA: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019-2030 (USD BILLION)
TABLE 89 CHINA: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019-2030 (USD BILLION)
TABLE 90 CHINA: NANOBODY MARKET, BY END USER, 2019-2030 (USD BILLION)
TABLE 91 INDIA: NANOBODY MARKET, BY TYPE, 2019-2030 (USD BILLION)
TABLE 92 INDIA: NANOBODY MARKET, BY APPLICATION, 2019-2030 (USD BILLION)
TABLE 93 INDIA: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019-2030 (USD BILLION)
TABLE 94 INDIA: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019-2030 (USD BILLION)
TABLE 95 INDIA: NANOBODY MARKET, BY END USER, 2019-2030 (USD BILLION)
TABLE 96 SOUTH KOREA: NANOBODY MARKET, BY TYPE, 2019-2030 (USD BILLION)
TABLE 97 SOUTH KOREA: NANOBODY MARKET, BY APPLICATION, 2019-2030 (USD BILLION)
TABLE 98 SOUTH KOREA: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019-2030 (USD BILLION)
TABLE 99 SOUTH KOREA: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019-2030 (USD BILLION)
TABLE 100 SOUTH KOREA: NANOBODY MARKET, BY END USER, 2019-2030 (USD BILLION)
TABLE 101 AUSTRALIA: NANOBODY MARKET, BY TYPE, 2019-2030 (USD BILLION)
TABLE 102 AUSTRALIA: NANOBODY MARKET, BY APPLICATION, 2019-2030 (USD BILLION)
TABLE 103 AUSTRALIA: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019-2030 (USD BILLION)
TABLE 104 AUSTRALIA: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019-2030 (USD BILLION)
TABLE 105 AUSTRALIA: NANOBODY MARKET, BY END USER, 2019-2030 (USD BILLION)
TABLE 106 REST OF ASIA-PACIFIC: NANOBODY MARKET, BY TYPE, 2019-2030 (USD BILLION)
TABLE 107 REST OF ASIA-PACIFIC: NANOBODY MARKET, BY APPLICATION, 2019-2030 (USD BILLION)
TABLE 108 REST OF ASIA-PACIFIC: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019-2030 (USD BILLION)
TABLE 109 REST OF ASIA-PACIFIC: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019-2030 (USD BILLION)
TABLE 110 REST OF ASIA-PACIFIC: NANOBODY MARKET, BY END USER, 2019-2030 (USD BILLION)
TABLE 111 REST OF THE WORLD: NANOBODY MARKET, BY REGION, 2019-2030(USD BILLION)
TABLE 112 REST OF THE WORLD: NANOBODY MARKET, BY TYPE, 2019-2030 (USD BILLION)
TABLE 113 REST OF THE WORLD: NANOBODY MARKET, BY APPLICATION, 2019-2030 (USD BILLION)
TABLE 114 REST OF THE WORLD: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019-2030 (USD BILLION)
TABLE 115 REST OF THE WORLD: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019-2030 (USD BILLION)
TABLE 116 REST OF THE WORLD: NANOBODY MARKET, BY END USER, 2019-2030 (USD BILLION)
TABLE 117 MIDDLE EAST: NANOBODY MARKET, BY TYPE, 2019-2030 (USD BILLION)
TABLE 118 MIDDLE EAST: NANOBODY MARKET, BY APPLICATION, 2019-2030 (USD BILLION)
TABLE 119 MIDDLE EAST: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019-2030 (USD BILLION)
TABLE 120 MIDDLE EAST: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019-2030 (USD BILLION)
TABLE 121 MIDDLE EAST: NANOBODY MARKET, BY END USER, 2019-2030 (USD BILLION)
TABLE 122 AFRICA: NANOBODY MARKET, BY TYPE, 2019-2030 (USD BILLION)
TABLE 123 AFRICA: NANOBODY MARKET, BY APPLICATION, 2019-2030 (USD BILLION)
TABLE 124 AFRICA: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019-2030 (USD BILLION)
TABLE 125 AFRICA: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019-2030 (USD BILLION)
TABLE 126 AFRICA: NANOBODY MARKET, BY END USER, 2019-2030 (USD BILLION)
TABLE 127 LATIN AMERICA: NANOBODY MARKET, BY TYPE, 2019-2030 (USD BILLION)
TABLE 128 LATIN AMERICA: NANOBODY MARKET, BY APPLICATION, 2019-2030 (USD BILLION)
TABLE 129 LATIN AMERICA: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019-2030 (USD BILLION)
TABLE 130 LATIN AMERICA: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019-2030 (USD BILLION)
TABLE 131 LATIN AMERICA: NANOBODY MARKET, BY END USER, 2019-2030 (USD BILLION)
TABLE 132 MAJOR PLAYERS IN THE GLOBAL NANOBODY MARKET
TABLE 133 MOST ACTIVE PLAYER IN THE GLOBAL NANOBODY MARKET
TABLE 134 PRODUCT LAUNCH/PRODUCT APPROVAL
TABLE 135 MERGER/ ACQUISITION
TABLE 136 PARTNERSHIP/ AGREEMENT/COLLABORATION
TABLE 137 SANOFI: PRODUCTS OFFERED
TABLE 138 SANOFI: KEY DEVELOPMENTS
TABLE 139 MERCK KGAA: PRODUCTS OFFERED
TABLE 140 MERCK KGAA: KEY DEVELOPMENTS
TABLE 141 BIOCYTOGEN: PRODUCTS OFFERED
TABLE 142 BIOCYTOGEN: KEY DEVELOPMENTS
TABLE 143 PROTEINTECH GROUP, INC.: PRODUCTS OFFERED
TABLE 144 NOVARTIS AG: PRODUCTS OFFERED
TABLE 145 GENSCRIPT: PRODUCTS OFFERED
TABLE 146 SENSEI BIOTHERAPEUTICS: PRODUCTS OFFERED
TABLE 147 SENSEI BIOTHERAPEUTICS: KEY DEVELOPMENTS
TABLE 148 BERONI GROUP: PRODUCTS OFFERED
TABLE 149 BERONI GROUP: KEY DEVELOPMENTS
TABLE 150 EXEVIR BIO BV.: PRODUCTS OFFERED
TABLE 151 TAISHO PHARMACEUTICAL HOLDINGS CO., LTD: PRODUCTS OFFERED
TABLE 152 DIOSCURE THERAPEUTICS SE: PRODUCTS OFFERED

LIST OF FIGURES

FIGURE 1 MARKET SYNOPSIS
FIGURE 2 GLOBAL NANOBODY MARKET STRUCTURE
FIGURE 3 BOTTOM-UP AND TOP-DOWN APPROACHES
FIGURE 4 MARKET DYNAMICS: GLOBAL NANOBODY MARKET
FIGURE 5 DRIVER IMPACT ANALYSIS
FIGURE 6 RESTRAINT IMPACT ANALYSIS
FIGURE 7 VALUE CHAIN ANALYSIS OF THE GLOBAL NANOBODY MARKET
FIGURE 8 PORTER'S FIVE FORCES ANALYSIS: GLOBAL NANOBODY MARKET
FIGURE 9 GLOBAL NANOBODY MARKET, TYPE SEGMENT ATTRACTIVENESS, (USD BILLION)
FIGURE 10 GLOBAL NANOBDOY MARKET, BY TYPE, 2022 & 2030 (USD BILLION)
FIGURE 11 GLOBAL NANOBDOY MARKET SHARE (%), BY TYPE, 2022
FIGURE 12 GLOBAL NANOBODY MARKET, APPLICATION SEGMENT ATTRACTIVENESS, (USD BILLION)
FIGURE 13 GLOBAL NANOBDOY MARKET, BY APPLICATION, 2022 & 2030 (USD BILLION)
FIGURE 14 GLOBAL NANOBDOY MARKET SHARE (%), BY APPLICATION, 2022
FIGURE 15 GLOBAL NANOBODY MARKET, END USER SEGMENT ATTRACTIVENESS, (USD BILLION)
FIGURE 16 GLOBAL NANOBDOY MARKET, BY END USER, 2022 & 2030 (USD BILLION)
FIGURE 17 GLOBAL NANOBDOY MARKET SHARE (%), BY END USER, 2022
FIGURE 18 GLOBAL: NANOBODY MARKET, BY REGION 2022 & 2030 (USD BILLION)
FIGURE 19 GLOBAL: NANOBODY MARKET SHARE (%), BY REGION, 2022
FIGURE 20 NORTH AMERICA MARKET ANALYSIS: NANOBODY MARKET, 2019-2030 (USD BILLION)
FIGURE 21 NORTH AMERICA: NANOBODY MARKET, BY COUNTRY 2022 & 2030 (USD BILLION)
FIGURE 22 NORTH AMERICA: NANOBODY MARKET SHARE (%), BY COUNTRY 2022
FIGURE 23 EUROPE MARKET ANALYSIS: NANOBODY MARKET, 2019-2030 (USD BILLION)
FIGURE 24 EUROPE: NANOBODY MARKET, BY COUNTRY 2022 & 2030 (USD BILLION)
FIGURE 25 EUROPE: NANOBODY MARKET SHARE (%), BY COUNTRY 2022
FIGURE 26 ASIA-PACIFIC MARKET ANALYSIS: NANOBODY MARKET, 2019-2030 (USD BILLION)
FIGURE 27 ASIA PACIFIC NANOBODY MARKET SHARE, BY COUNTRY 2022 & 2030 (USD BILLION)
FIGURE 28 ASIA PACIFIC: NANOBODY MARKET SHARE (%), BY COUNTRY, 2022
FIGURE 29 REST OF THE WORLD MARKET ANALYSIS: NANOBODY MARKET, 2019-2030 (USD BILLION)
FIGURE 30 REST OF THE WORLD NANOBODY MARKET SHARE, BY REGION 2022 & 2030 (USD BILLION)
FIGURE 31 REST OF THE WORLD: NANOBODY MARKET SHARE (%), BY REGION, 2022
FIGURE 32 BENCHMARKING OF MAJOR COMPETITORS
FIGURE 33 MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN THE GLOBAL NANOBODY MARKET
FIGURE 34 GLOBAL NANOBODY MARKET: COMPETITIVE LANDSCAPE
FIGURE 35 MAJOR PLAYERS SALES, 2022 (USD BILLION)
FIGURE 36 MAJOR PLAYER R&D EXPENDITURE, 2022 (USD BILLION)
FIGURE 37 SANOFI: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 38 SANOFI: SWOT ANALYSIS
FIGURE 39 MERCK KGAA: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 40 MERCK KGAA: SWOT ANALYSIS
FIGURE 41 NOVARTIS AG: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 42 NOVARTIS AG: SWOT ANALYSIS
FIGURE 43 GENSCRIPT: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 44 GENSCRIPT: SWOT ANALYSIS
FIGURE 45 SENSEI BIOTHERAPEUTICS: SWOT ANALYSIS
FIGURE 46 BERONI GROUP: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 47 TAISHO PHARMACEUTICAL HOLDINGS CO., LTD: FINANCIAL OVERVIEW SNAPSHOT

Have a question?

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Christine Sirois

Manager - Americas

+1-860-674-8796

SEE OUR FAQ